Passiglia et al. [26] performed a meta-analysis of all phase II/III randomized clinical trials comparing PD1/PDL1 inhibitors versus docetaxel in pretreated NSCLC patients. This evidence concerns the gene CD274 and non-small cell lung carcinoma.